Sun Pharma is committed to advancing patient care in psoriasis, alopecia areata, and acne. At the 2026 AAD Annual Meeting in Denver, Colorado, the company presented 14 abstracts showcasing its latest research and developments in these areas.
Among the highlights, ILUMYA targets moderate-to-severe plaque psoriasis and nail psoriasis, while LEQSELVI is aimed at treating severe alopecia areata. Additionally, WINLEVI is indicated for acne vulgaris and is used in combination therapies.
However, not all news was positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about its future in the market.
On a brighter note, Nidlegy achieved complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, indicating promising potential for this treatment.
Furthermore, the GLIOSTELLA study in late-line glioblastoma has completed enrollment in the U.S., marking a significant step forward for Sun Pharma’s oncology pipeline.
Ahmad Naim, MD, commented, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.”
Looking ahead, a new submission for Nidlegy is being prepared following the withdrawal of a prior Marketing Authorization Application in 2025, signaling ongoing efforts to bring this treatment to market.
As Sun Pharma continues to innovate, observers are keenly watching how these developments will impact the company’s position in the competitive pharmaceutical landscape.
